Selected article for: "disease severity and MERS cov"

Author: Pitocco, Dario; Tartaglione, Linda; Viti, Luca; Di Leo, Mauro; Pontecorvi, Alfredo; Caputo, Salvatore
Title: SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons?
  • Cord-id: yyk6af7u
  • Document date: 2020_4_23
  • ID: yyk6af7u
    Snippet: Abstract Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV 3) demonstrated inhibition
    Document: Abstract Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV 3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and 4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a plausible approach to mitigate Covid-19.

    Search related documents:
    Co phrase search for related documents